365 related articles for article (PubMed ID: 29171009)
1. Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.
Zhao S; Gao F; Zhang Y; Zhang Z; Zhang L
Int J Cancer; 2018 Apr; 142(8):1676-1688. PubMed ID: 29171009
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
3. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J
BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
5. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
[TBL] [Abstract][Full Text] [Related]
8. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.
Frederickson AM; Arndorfer S; Zhang I; Lorenzi M; Insinga R; Arunachalam A; Burke TA; Simon GR
Immunotherapy; 2019 Apr; 11(5):407-428. PubMed ID: 30712477
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia.
Zhang XF; De-Sheng LV; Li M; Sun GE; Liu CH
Indian J Cancer; 2017; 54(1):104-114. PubMed ID: 29199672
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Lu S; Cheng Y; Zhou CC; Wang J; Chih-Hsin Yang J; Zhang PH; Zhang XQ; Wang X; Orlando M; Wu YL
Clin Lung Cancer; 2016 Sep; 17(5):e103-e112. PubMed ID: 27236385
[TBL] [Abstract][Full Text] [Related]
17. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
Behera M; Pillai RN; Owonikoko TK; Kim S; Steuer C; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
J Thorac Oncol; 2015 Aug; 10(8):1142-7. PubMed ID: 26200267
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O; Rothschild SI; Li Q; Matter-Walstra K; Zippelius A; Betticher DC; Früh M; Stahel RA; Cathomas R; Rauch D; Pless M; Peters S; Froesch P; Zander T; Schneider M; Biaggi C; Mach N; Ochsenbein AF;
Clin Lung Cancer; 2017 May; 18(3):303-309. PubMed ID: 27993482
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
